tiprankstipranks
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
TipRanksstock market overviewJazz Pharmaceuticals Stock Analysis & Ratings

Jazz Pharmaceuticals Stock Analysis & Ratings

0 Followers

J7Z Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€150.52
Volume0.00
Average Volume (3M)22.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta0.08
Next EarningsNov 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)N/A
Shares Outstanding62,442,548
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume22
P/B Ratio-2.00
P/S Ratio3.79
P/CF Ratio13.80
P/FCF Ratio16.90
Total Debt€2.03B
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside28.55% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering10


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

J7Z FAQ

What was Jazz Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
What is Jazz Pharmaceuticals’s price target?
The average price target for Jazz Pharmaceuticals is €193.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is €209.48 ,the lowest forecast is €178.30. The average price target represents 28.55% Increase from the current price of €150.52.
    What do analysts say about Jazz Pharmaceuticals?
    Jazz Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
      When is Jazz Pharmaceuticals’s upcoming earnings report date?
      Jazz Pharmaceuticals’s upcoming earnings report date is Nov 08, 2022 which is in 86 days.
        How were Jazz Pharmaceuticals’s earnings last quarter?
        Jazz Pharmaceuticals released its earnings results on Aug 03, 2022. The company reported €4.19 earnings per share for the quarter, beating the consensus estimate of €4.071 by €0.119.
          Is Jazz Pharmaceuticals overvalued?
          According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Jazz Pharmaceuticals pay dividends?
            Jazz Pharmaceuticals does not currently pay dividends.
            What is Jazz Pharmaceuticals’s EPS estimate?
            Jazz Pharmaceuticals’s EPS estimate is €4.54.
              How many shares outstanding does Jazz Pharmaceuticals have?
              Currently, no data Available
              What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
              Jazz Pharmaceuticals reported an EPS of €4.19 in its last earnings report, beating expectations of €4.071. Following the earnings report the stock price went down -0.414%.
                Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
                Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 234M.

                  ---

                  Jazz Pharmaceuticals Stock Analysis

                  Smart ScoreUnderperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  3

                  Analyst Forecast

                  Strong Buy
                  Average Price Target: €193.50

                  Blogger Sentiment

                  Bullish
                  DE:J7Z Sentiment 75% Sector Average 69%

                  Insider Transactions

                  ▼ Sold Shares
                  Worth $7.6M over the Last 3 Months

                  News Sentiment

                  Neutral
                  Bullish 100% Bearish 0%

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  7.84%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -1.41%
                  Trailing 12-Months
                  Asset Growth
                  -15.23%
                  Trailing 12-Months
                  The Jazz Pharmaceuticals Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Jazz Pharmaceuticals

                  Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Endo International
                  Iterum Therapeutics
                  Perrigo Company
                  GH Research
                  Avadel Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis